WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Economy in transition GNI / capita (US$): 11'4001 Infant (under 12 months) mortality rate: 82
GDP / capita (US$): 24'4511 Child (under 5 years) mortality rate: 102

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 143'965  143'888  143'761  143'597  143'421  146'397  147'564  138'059 
Births 1'833  1'852  1'860  1'855  1'836  1'329  1'999  2'259 
Surviving infants 1'820  1'838  1'845  1'840  1'821  1'304  1'954  2'197 
Pop. less than 5 years 9'561  9'355  9'167  8'841  8'459  6'435  11'524  10'546 
Pop. less than 15 years 24'894  24'220  23'609  22'894  22'176  26'708  33'796  29'767 
Female 15-49 years 34'238  34'626  35'130  35'749  36'423  39'452  35'705  36'376 

Number of reported cases

(Click for retrospective incidence data for Russian Federation (the))
Diphtheria
ChartChart
  771  1'211 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  178  843  4'711  2'339  2'123  4'800  18'370 
Mumps
ChartChart
  1'106  190  267  282  394  40'976 
Pertussis
ChartChart
  8'232  6'452  4'705  4'510  7'220  29'983  24'960 
Polio*
ChartChart
 
Rubella
ChartChart
  38  25  72  233  1'003  457'378 
Rubella (CRS)
ChartChart
  11 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  18  13  11  21  33 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Russian Federation (the))
Vaccine year result method % card seen                                                
BCG          96  96  96  96  96  96 
DTP1          97 
DTP3          97  97  97  97  97  96 
DTP4          97  97  96 
IPV1         
HepB_BD         
HepB3          97  97  97  97  97  10 
Hib3          90 
JapEnc         
MCV1          98  98  98  98  98  97 
MCV2          97  97  97  97  97  86 
MenA         
PCV1         
PCV2          75 
PCV3          35 
Pol3          97  97  97  98  98  97 
Rota1         
RotaC         
RCV1          98  98  98  98  98 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Russian Federation (the))
BCG
ChartChart
  96  96  96  96  96  96 
DTP1
ChartChart
  97  97  97  97  97  97 
DTP3
ChartChart
  97  97  97  97  97  96 
HepB3
ChartChart
  97  97  97  97  97 
HepB_BD
ChartChart
 
Hib3
ChartChart
 
IPV1
  97  97 
MCV1
ChartChart
  98  98  98  98  98  97 
MCV2
ChartChart
  97  97  97  97  97  86 
PCV3
ChartChart
  35 
Pol3
ChartChart
  97  97  97  98  98  97 
RCV1
ChartChart
  98  98  98  98  98  97 
RotaC
ChartChart
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
aP >= 5 years; Yes
BCG 3 days; 7 years; Yes
Dip + 10 years; Yes
DT 3, 4.5 months; 1 year; Yes
DTaPHibHepIPV 3, 4.5, 6, 18 months; No
DTaPHibIPV 3, 4.5, 6, 18 months; No
DTwP 3, 4.5, 6, 18 months; Yes
DTwPHep 6 months; Yes
HepA_Adult 1st contact; +6-12 months; No
HepA_Pediatric >=1 year; +6-12 months; No
HepB_Adult 1st contact; +1, +6 months; Yes
HepB_Pediatric 1 day; 1, 6 months; Yes
HIB 3, 4.5, 6, 18 months; Yes risk groups
HPV 13 years; No
Influenza_Adult >= 60 years; Pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric >6 months; Yes and children with chronic diseases
IPV 3, 4.5 months; Yes
Measles 12 months; 6, 18-55 years; Yes
MenAC No By epidemiological indications
MenACWY-135 conj No For pilgrims
MM 12 months; 6 years; Yes
MMR 12 months; 6 years; No
Mumps 12 months; 6 years; Yes
OPV 6, 18, 20 months; 14 years; Yes
Pneumo_conj 2, 4.5, 15 months; Yes
Pneumo_ps >= 18 years; No
Rotavirus 2, 4.5 months; No
Rubella 12 months; 6 years; Yes
Td 6-7, 14 years; +10 years; Yes
Tdap 3, 4.5, 6, 18 months; No
TT 5 years; Yes
Typhoid >= 18 years; No
Varicella 12 months; No
YF No 34/5000 dlya vyyezzhayushchikh v endemichnyye strany For travelers to endemic countries

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2'020  2'020           
Nº of districts with microplans that include activities to raise immunization coverage number 85  85           

System performance

Total Nº districts in country number     84  83  83  83  83 
Nº districts with DTP3 coverage >=80% number 85  85  83  83  83  83  83 
% of districts with DTP3 coverage >=80% From 0 to 100%     99  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 83  84  83  83  83  83  83 
% of districts with MCV1 coverage >=95% From 0 to 100%     99  100  100  100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  Yes  Yes  Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No    No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.